Kopran Ltd
Company Profile
Business description
Kopran Ltd is an Indian pharmaceutical company with integrated operations across formulations and Active Pharmaceutical Ingredients (APIs). The company is engaged in the development, manufacturing and marketing of pharmaceutical products for both domestic and international markets. Its formulations business focuses on oral solid dosage forms and other pharmaceutical products across a range of therapeutic categories. The API business manufactures a portfolio of APIs and intermediates. Its portfolio spans therapeutic areas such as anti-infectives, cardiovascular, gastroenterology, CNS and anti-diabetic products, along with specialized APIs including Atenolol and Sterile Carbapenems. It operates in a single reportable segment of the manufacturing of Formulation (Finished Dosage Form).
Contact
Dr. E. Moses Road
1076, Parijat House
Worli
MumbaiMH400 018
INDT: +91 2243661111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
1,024
Stocks News & Analysis
stocks
6 undervalued US shares that crushed earnings
stocks
Undervalued REIT offers attractive yield post earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 5.60 | 0.06% |
| CAC 40 | 8,532.69 | 46.91 | -0.55% |
| DAX 40 | 26,223.67 | 114.94 | -0.44% |
| Dow JONES (US) | 53,459.78 | 272.63 | -0.51% |
| FTSE 100 | 10,711.20 | 9.10 | -0.08% |
| HKSE | 25,471.15 | 17.92 | 0.07% |
| NASDAQ | 26,644.91 | 84.25 | -0.32% |
| Nikkei 225 | 67,460.73 | 1,759.52 | -2.54% |
| NZX 50 Index | 13,866.18 | 144.20 | 1.05% |
| S&P 500 | 7,745.06 | 40.70 | -0.52% |
| S&P/ASX 200 | 9,070.00 | 5.20 | 0.06% |
| SSE Composite Index | 3,990.30 | 7.65 | 0.19% |